---
layout: default
title: Rotigotine
description: "Rotigotine çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚åˆæ­¥è­‰æ“šç­‰ç´š L4ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 151
evidence_level: L4
indication_count: 10
---

# Rotigotine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L4</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Rotigotineï¼šå¾å¸•é‡‘æ£®æ°ç—‡åˆ°æ€è¦ºå¤±èª¿ç—‡

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Rotigotine å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Rotigotine åŸæœ¬ç”¨æ–¼æ²»ç™‚åŸç™¼æ€§å¸•é‡‘æ£®æ°ç—‡ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**æ€è¦ºå¤±èª¿ç—‡ (schizophrenia)** æœ‰æ•ˆï¼Œé€™å€‹é æ¸¬ç²å¾—å¤šç¯‡ PubMed æ–‡ç»æ”¯æŒï¼ŒåŒ…å«ç³»çµ±æ€§å›é¡§åŠè—¥ç†å­¸ç ”ç©¶ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | åŸç™¼æ€§å¸•é‡‘æ£®æ°ç—‡ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | attention deficit-hyperactivity disorderã€schizophreniaã€polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposisã€faciodigitogenital syndromeã€congenital disorder of glycosylation with defective fucosylationã€retinal dystrophy with or without extraocular anomaliesã€myopia X-linkedã€atypical glycine encephalopathyã€Charcot-Marie-Tooth disease, demyelinating, type 1Gã€myopia 26, X-linked, female-limited |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.996% |
| è­‰æ“šç­‰ç´š | L4 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 12 å¼µ |
| å»ºè­°æ±ºç­– | Worth Exploring |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. attention deficit-hyperactivity disorder</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">100.00%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Rotigotine æ˜¯ä¸€ç¨®ééº¥è§’é¡å¤šå·´èƒºä¿ƒæ•ˆåŠ‘ï¼Œå°æ‰€æœ‰äº”ç¨®å¤šå·´èƒºå—é«”äºå‹ï¼ˆD1-D5ï¼‰éƒ½æœ‰æ´»æ€§ï¼š

1. **å»£è­œå¤šå·´èƒºå—é«”ä½œç”¨**ï¼šRotigotine å° D1ã€D2ã€D3ã€D4ã€D5 å—é«”éƒ½æœ‰è¦ªå’ŒåŠ›ï¼Œé€™ç¨®å»£è­œä½œç”¨å¯èƒ½å°æ€è¦ºå¤±èª¿ç—‡çš„è¤‡é›œå¤šå·´èƒºå¤±èª¿æœ‰ç¨ç‰¹å„ªå‹¢ã€‚

2. **è² æ€§ç—‡ç‹€æ²»ç™‚æ½›åŠ›**ï¼šæ€è¦ºå¤±èª¿ç—‡çš„è² æ€§ç—‡ç‹€èˆ‡å‰é¡è‘‰çš®è³ªå¤šå·´èƒºåŠŸèƒ½ä½ä¸‹æœ‰é—œï¼ŒD1 å—é«”ä¿ƒæ•ˆä½œç”¨å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„ã€‚

3. **æŒçºŒè—¥ç‰©é‡‹æ”¾**ï¼šç©¿çš®è²¼ç‰‡åŠ‘å‹æä¾›ç©©å®šçš„è¡€ä¸­æ¿ƒåº¦ï¼Œå¯èƒ½æ¸›å°‘ç™‚æ•ˆæ³¢å‹•å’Œå‰¯ä½œç”¨ã€‚

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡ Rotigotine ç”¨æ–¼æ€è¦ºå¤±èª¿ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

### ç›¸é—œæ–‡ç»

å…±æ‰¾åˆ° 4 ç¯‡ç›¸é—œæ–‡ç»ï¼š

### é—œéµæ–‡ç»

1. **Xu et al. (2023)** - Cell Research
   - æ¨™é¡Œï¼šStructural genomics of the human dopamine receptor system
   - é¡å‹ï¼šåŸºç¤ç ”ç©¶
   - é‡é»ï¼šå ±å‘Šäº† Rotigotine èˆ‡æ‰€æœ‰äº”ç¨®äººé¡å¤šå·´èƒºå—é«”è¤‡åˆç‰©çš„å†·å‡é›»å­é¡¯å¾®é¡çµæ§‹ï¼Œæ­ç¤ºå…¶åœ¨ä¸åŒå—é«”çš„çµåˆåŸºç¤
   - [PubMed é€£çµ](https://pubmed.ncbi.nlm.nih.gov/37221270/)

2. **Sabe et al. (2019)** - Journal of Clinical Psychopharmacology
   - æ¨™é¡Œï¼šProdopaminergic Drugs for Treating the Negative Symptoms of Schizophrenia: Systematic Review and Meta-analysis of Randomized Controlled Trials
   - é¡å‹ï¼šç³»çµ±æ€§å›é¡§èˆ‡çµ±åˆåˆ†æ
   - é‡é»ï¼šä¿ƒå¤šå·´èƒºè—¥ç‰©å¯èƒ½ä½œç‚ºæ€è¦ºå¤±èª¿ç—‡è² æ€§ç—‡ç‹€çš„è¼”åŠ©æ²»ç™‚
   - [PubMed é€£çµ](https://pubmed.ncbi.nlm.nih.gov/31688399/)

3. **Brust et al. (2015)** - Biochemical Pharmacology
   - æ¨™é¡Œï¼šNew functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated G-beta-gamma signaling
   - é¡å‹ï¼šåŸºç¤ç ”ç©¶
   - é‡é»ï¼šæ¯”è¼ƒä¸åŒå¤šå·´èƒºè—¥ç‰©åœ¨ D2 å—é«”çš„åŠŸèƒ½æ´»æ€§
   - [PubMed é€£çµ](https://pubmed.ncbi.nlm.nih.gov/25449598/)

4. **Timmerman et al. (1990)** - European Journal of Pharmacology
   - æ¨™é¡Œï¼šThe potential antipsychotic activity of the partial dopamine receptor agonist (+)N-0437
   - é¡å‹ï¼šå‹•ç‰©ç ”ç©¶
   - é‡é»ï¼š(+)N-0437ï¼ˆRotigotine çš„å‰é«”åŒ–åˆç‰©ï¼‰å±•ç¾æ½›åœ¨æŠ—ç²¾ç¥ç—…æ´»æ€§ï¼Œä½†ä¸å¼•èµ·åƒµç›´ç—‡
   - [PubMed é€£çµ](https://pubmed.ncbi.nlm.nih.gov/1974516/)

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. schizophrenia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">100.00%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š100.00%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. faciodigitogenital syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. congenital disorder of glycosylation with defective fucosylation</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. retinal dystrophy with or without extraocular anomalies</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. myopia X-linked</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. atypical glycine encephalopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. Charcot-Marie-Tooth disease, demyelinating, type 1G</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. myopia 26, X-linked, female-limited</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›ç½²è—¥è¼¸å­—ç¬¬024933è™Ÿ | ç´æ™®æ´›ç©¿çš®è²¼ç‰‡åŠ‘ 2 æ¯«å…‹/24å°æ™‚ | ç©¿çš®è²¼ç‰‡åŠ‘ | åŸç™¼æ€§å¸•é‡‘æ£®æ°ç—‡ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬024934è™Ÿ | ç´æ™®æ´›ç©¿çš®è²¼ç‰‡åŠ‘ 4 æ¯«å…‹/24å°æ™‚ | ç©¿çš®è²¼ç‰‡åŠ‘ | åŸç™¼æ€§å¸•é‡‘æ£®æ°ç—‡ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬024935è™Ÿ | ç´æ™®æ´›ç©¿çš®è²¼ç‰‡åŠ‘ 6 æ¯«å…‹/24å°æ™‚ | ç©¿çš®è²¼ç‰‡åŠ‘ | åŸç™¼æ€§å¸•é‡‘æ£®æ°ç—‡ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬024936è™Ÿ | ç´æ™®æ´›ç©¿çš®è²¼ç‰‡åŠ‘ 8 æ¯«å…‹/24å°æ™‚ | ç©¿çš®è²¼ç‰‡åŠ‘ | åŸç™¼æ€§å¸•é‡‘æ£®æ°ç—‡ |

## å®‰å…¨æ€§è€ƒé‡

### é‡è¦è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ | ä¾†æº |
|-------------|---------|------|
| Morphine | ä¸­åº¦ | DDInter |
| Metoclopramide | ä¸­åº¦ | DDInter |
| Ethanol | ä¸­åº¦ | DDInter |
| Thalidomide | ä¸­åº¦ | DDInter |
| Promethazine | ä¸­åº¦ | DDInter |
| Codeine | ä¸­åº¦ | DDInter |
| Diphenhydramine | ä¸­åº¦ | DDInter |

### è—¥ç†å­¸æ¨™é¶

| æ¨™é¶ | åŸºå› åç¨± |
|-----|---------|
| D1 receptor | DRD1 |
| D2 receptor | DRD2 |
| D3 receptor | DRD3 |
| D4 receptor | DRD4 |
| D5 receptor | DRD5 |

### ç‰¹æ®Šæ³¨æ„äº‹é …

- **å—œç¡èˆ‡çªç™¼ç¡çœ **ï¼šå¯èƒ½å½±éŸ¿é§•é§›èƒ½åŠ›
- **è¡å‹•æ§åˆ¶éšœç¤™**ï¼šèˆ‡å…¶ä»–å¤šå·´èƒºä¿ƒæ•ˆåŠ‘é¡ä¼¼çš„é¢¨éšª
- **çš®è†šåæ‡‰**ï¼šè²¼ç‰‡éƒ¨ä½å¯èƒ½å‡ºç¾å±€éƒ¨åæ‡‰

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šAlcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and...
- å»ºè­°ï¼šPatients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities r...



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**æ°£å–˜ (Asthma)** ğŸŸ¡ Moderate
- Rotigotine (transdermal patch) contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life threatening or less severe asthmatic episodes in certain susceptible people.  Sulfite sensitivity ...

**å¿ƒè¡€ç®¡ç–¾ç—… (Cardiovascular Diseases)** ğŸŸ¡ Moderate
- Some patients treated with rotigotine exhibited an increased pulse, greater than 100 beats per minute, while supine or standing.  Also, like other dopaminergic agents, rotigotine might impair the systemic regulation of blood pressure causing postural...

**Water-Electrolyte Imbalance** ğŸŸ¡ Moderate
- Patients taking rotigotine had a higher incidence of weight gain associated with fluid retention, when compared with patients taking placebo.  Weight gain and fluid retention should be monitored in patients using rotigotine, specially in those with c...

**ä½è¡€å£“ (Hypotension)** ğŸŸ¢ Minor
- Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson's disease sinc...

**Psychotic Disorders** ğŸŸ¢ Minor
- Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medicatio...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šWorth Exploring**

**ç†ç”±ï¼š**
1. å»£è­œå¤šå·´èƒºå—é«”ä½œç”¨æä¾›ç¨ç‰¹çš„è—¥ç†å­¸å„ªå‹¢
2. ç©¿çš®è²¼ç‰‡åŠ‘å‹å¯ç¢ºä¿ç©©å®šè¡€ä¸­æ¿ƒåº¦
3. æ­·å²ç ”ç©¶é¡¯ç¤ºç›¸é—œåŒ–åˆç‰©å…·æœ‰æ½›åœ¨æŠ—ç²¾ç¥ç—…æ´»æ€§
4. ç³»çµ±æ€§å›é¡§æ”¯æŒä¿ƒå¤šå·´èƒºè—¥ç‰©ç”¨æ–¼è² æ€§ç—‡ç‹€
5. å°ç£å·²æœ‰å¤šç¨®åŠ‘é‡è¦æ ¼ä¸Šå¸‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- è‡¨åºŠè©¦é©—è©•ä¼° Rotigotine è²¼ç‰‡è¼”åŠ©æ²»ç™‚æ€è¦ºå¤±èª¿ç—‡è² æ€§ç—‡ç‹€çš„ç™‚æ•ˆ
- ç¢ºå®šæœ€é©åŠ‘é‡ç¯„åœï¼ˆå¯èƒ½èˆ‡å¸•é‡‘æ£®æ°ç—‡ç”¨é‡ä¸åŒï¼‰
- è©•ä¼°èˆ‡æŠ—ç²¾ç¥ç—…è—¥ç‰©ä½µç”¨çš„å®‰å…¨æ€§å’Œäº¤äº’ä½œç”¨


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Aluminum Oxide]({{ "/drugs/aluminum_oxide/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Dl-Alpha-Tocopherol]({{ "/drugs/dl-alpha-tocopherol/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Prednisolone Acetate]({{ "/drugs/prednisolone_acetate/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Acebutolol]({{ "/drugs/acebutolol/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Ritonavir]({{ "/drugs/ritonavir/" | relative_url }}) - è­‰æ“šç­‰ç´š L4

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Rotigotineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/rotigotine/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_rotigotine,
  title = {Rotigotineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/rotigotine/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
